vision trial supports lupsma-targeting therapy for mcrpc | michael morris
Published 3 years ago • 910 plays • Length 7:44Download video MP4
Download video MP3
Similar videos
-
3:16
updated therap data further support lupsma for mcrpc | michael hofman
-
5:29
key considerations for the vision trial of lupsma in mcrpc | mary-ellen taplin
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:47
challenges in radioligand therapy for patients with mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
2:08
phase1b trial investigates atezolizumab and radium-223 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
0:46
dr. morris on mechanism of action for radium-223
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
1:46
turning clinical results into change for patients with prostate cancer
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
7:14
vision study
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
6:56
oncological value of lutetium-177-psma therapy for mcrpc